We found for
When Generic Measures Fail to Reflect What Matters to Patients: Three Case Studies

Learnings from the Assessments of Entrectinib and Larotrectinib: Health Technology Assessment Challenges Associated with Tumour-Agnostic Therapies

Making Outcome-Based Payment a Reality in the NHS. Phase Two: Practical Considerations

How is Quality of Life Measured for Health Technology Assessments?

Why we need a new Outcomes-based Value Attribution Framework for Combination Regimens in Oncology
